Introduction

Imagine slowly losing the ability to read your favorite book, recognize your loved ones' faces, or drive safely to familiar places. For millions of people worldwide, this isn't just a hypothetical scenario — it's the daily reality of living with Age-related Macular Degeneration (AMD). As one of the leading causes of vision loss in older adults, AMD has long posed a frustrating challenge for patients and doctors alike. But that narrative is starting to change.

At Global Ubal Eye Center in Incheon, South Korea, we’ve witnessed firsthand how cutting-edge research and a human-centered approach to eye care can bring not just hope, but real, measurable progress. Led by Dr. Heecheol Bae, MD, PhD, and supported by a multilingual, internationally-minded team, our clinic is dedicated to integrating the latest global breakthroughs with deeply personalized patient care.

In this comprehensive article, we explore how revolutionary therapies are transforming the treatment landscape for both wet and dry forms of AMD. Whether you are a patient, a caregiver, or simply someone concerned about your long-term vision, this guide will help you understand what’s new, what’s next, and what you can do now to protect your sight.

What is AMD — a quick refresher

The macula is the central part of the retina, responsible for the sharp, fine-detail vision we use to read, recognize faces, and drive safely. In AMD, the cells in this region begin to deteriorate, leading to central vision loss. While peripheral vision often remains intact, the impact of central vision loss on quality of life can be devastating.

There are two main types:

• Wet AMD: Caused by the growth of abnormal blood vessels under the retina, which leak blood and fluid, damaging macular tissue. This form is typically more aggressive and leads to faster vision loss.
• Dry AMD: Characterized by the gradual thinning and death of the macula's light-sensitive cells. It progresses more slowly but accounts for the majority of AMD cases. In later stages, it leads to geographic atrophy (GA), which can be equally debilitating.

For years, the standard treatment for wet AMD has involved anti-VEGF injections that block the formation of new, leaky blood vessels. Dry AMD, until recently, had no approved treatment beyond lifestyle recommendations, antioxidant vitamins (AREDS2), and regular monitoring.

Why new treatments are needed

Despite past successes, there are major gaps in AMD care:

1. Treatment burden: Anti-VEGF injections must be administered every 4–8 weeks. For many older patients, this schedule is exhausting and logistically challenging.
2. Access disparities: In countries with limited ophthalmologic infrastructure, patients miss doses or never get diagnosed early enough.
3. Unmet needs in dry AMD: No meaningful disease-modifying therapy existed for geographic atrophy until very recently.
4. Lack of personalization: Treatments have historically taken a one-size-fits-all approach, ignoring genetic, lifestyle, and demographic differences.

At Global Ubal Eye Center, we regularly see patients who have been misdiagnosed, untreated, or told there’s "nothing to be done." Many travel from Mongolia, Japan, Russia, and Southeast Asia because they’re seeking more than a prescription — they’re looking for hope and a plan. And that’s where these new treatments make a difference.

How the future is shifting: key treatment frontiers

1. Longer-acting anti-VEGF injections & dual-pathway inhibitors (wet AMD)

Anti-VEGF drugs like Aflibercept (Eylea) and Ranibizumab (Lucentis) have revolutionized wet AMD treatment. However, they require monthly or bimonthly injections into the eye, which can be a heavy burden.

New drugs and delivery systems are changing this. Agents like Faricimab (Vabysmo) target both VEGF-A and Ang-2 pathways, allowing longer intervals between injections. Some patients can go 16 weeks between treatments.

Pipeline innovations include:

• Sozinibercept (OPT-302): A novel biologic targeting VEGF-C/D, showing promising results when combined with anti-VEGF-A agents.
• Gene therapy (RGX-314): Offers the potential for one-time subretinal injection to deliver sustained anti-VEGF effect for years.

At our clinic, we’ve begun assessing eligibility for extended-interval regimens and trials, especially for patients from overseas who cannot attend frequent visits.

2. The arrival of geographic atrophy therapies (dry AMD)

This is the most significant advancement in decades for dry AMD:

• Pegcetacoplan (SYFOVRE®): Recently approved to slow GA progression by inhibiting complement C3. Administered monthly via injection.
• Avacincaptad pegol (IZERVAY™): Another intravitreal therapy targeting complement C5, showing efficacy in delaying GA lesion growth.
• Sefaxersen: In clinical trials, using antisense oligonucleotides to inhibit complement factor B, a crucial part of the inflammatory cascade.

These treatments offer the first tangible hope to patients who have been told to simply wait and watch.

3. Regenerative medicine & retinal implants

The next frontier isn’t just preservation — it’s restoration.

• Stem-cell therapy: Transplantation of lab-grown retinal pigment epithelium (RPE) cells to replace degenerated tissue. Early trials show encouraging safety and efficacy.
• OpRegen (Lineage Cell Therapeutics): Subretinal delivery of RPE cells for GA. Some patients have shown visual improvement.
• Retinal implants: Such as the Argus II, designed to stimulate the retina in advanced degenerative conditions. These are early-stage but hint at what may be possible.

While we don’t yet offer these as standard treatment, our research partnerships and technology watch ensure we are ready when the time is right.

Global Ubal Eye Center's approach: Innovation + Human Touch

Here’s how we integrate cutting-edge science with compassionate care:

• Advanced diagnostics: We employ multimodal imaging, including OCT-Angiography and Fundus Autofluorescence, to detect subtle AMD changes before they cause vision loss.
• Genetic & risk profiling: We factor in smoking history, cardiovascular risk, diet, and family history to personalise therapy.
• Trial access: For eligible patients, we facilitate enrolment in multinational studies.
• Multilingual care: Our staff speaks English, Russian, Mongolian, Japanese, and Korean, ensuring nothing is lost in translation.
• Patient education: We provide AMD education kits and explain each treatment step in plain language.

What patients should know and ask

We always encourage patients to be proactive:

• “Do I have wet or dry AMD?”

• “How quickly is my condition progressing?”

• “Are there treatments or clinical trials available to me?”

• “What lifestyle habits can help?”

• “Can I space out my treatments without compromising results?”

AMD is not one disease — it’s a spectrum. And where you are on that spectrum will shape your choices.

A real-world case: Vision preserved, dignity maintained

A 64-year-old engineer from Vladivostok came to us after being diagnosed with dry AMD. His central vision was deteriorating, and local doctors had no options to offer.

Our imaging showed early geographic atrophy. After discussing risks and benefits, we enrolled him in a Pegcetacoplan trial. Over the next 18 months, the progression slowed by nearly 40% compared to baseline predictions. Most importantly, he retained the ability to read and write — his two greatest passions.

He still sends us postcards every few months, grateful that he can see the words he writes.

Conclusion: Reimagining the future of AMD

Macular degeneration is no longer a life sentence. It’s a challenge — yes — but no longer one without tools or hope. We are standing at the edge of a new era in ophthalmology, one where the prognosis for AMD is no longer dictated by inevitability but shaped by innovation.

With longer-lasting anti-VEGF drugs, newly approved treatments for geographic atrophy, regenerative medicine in active development, and increased global access to advanced care, patients now have more reason than ever to feel optimistic.

At Global Ubal Eye Center, we believe the future of AMD care lies not only in advanced science, but in the compassionate application of that science to the unique story of each patient. Whether you are a retiree from Seoul or an international traveler seeking expert care, our clinic is here to help you see a clearer future.

If you or someone you love has been affected by AMD, don’t wait. Reach out, ask questions, and explore your options. The earlier we intervene, the more we can preserve — not just vision, but quality of life.